2012-10-10 21:32:02 - New Pharmaceuticals research report from Global Markets Direct is now available from Fast Market Research

Global Market Direct's pharmaceuticals report, "Ablynx NV - Product Pipeline Review - 2012" provides data on the Ablynx NV's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Ablynx NV's corporate website, SEC filings, investor presentations and featured press releases, both from Ablynx NV and industry-specific third party sources, put together by Global Markets Direct's team.


Full Report Details at
- www.fastmr.com/prod/468502_ablynx_nv_product_pipeline_review_201 ..


Scope

* Ablynx NV - Brief Ablynx NV overview including business description, key information and facts, and its locations and subsidiaries.
*

Review of current pipeline of Ablynx NV human therapeutic division.
* Overview of pipeline therapeutics across various therapy areas.
* Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
* Product profiles for late stage and clinical stage products of Ablynx NV with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
* Recent updates of the Ablynx NV's pipeline in the last quarter.
* Key discontinued and dormant projects.
* Latest news and deals relating to the products.

Reasons to buy

* Evaluate Ablynx NV's strategic position with total access to detailed information on its product pipeline.
* Assess the growth potential of Ablynx NV in its therapy areas of focus.
* Identify new drug targets and therapeutic classes in the Ablynx NV's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
* Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
* Exploit collaboration and partnership opportunities with Ablynx NV.
* Avoid Intellectual Property Rights related issues.
* Explore the dormant and discontinued projects of Ablynx NV and identify potential opportunities in those areas.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Ablynx NV Snapshot
Ablynx NV Overview
Key Information
Key Facts
Ablynx NV - Research and Development Overview
Key Therapeutic Areas
Ablynx NV - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
Ablynx NV - Pipeline Products Glance
Ablynx NV Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Ablynx NV - Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Ablynx NV - Drug Profiles
ALX-0061
Product Description
Mechanism of Action
R&D Progress
ALX-0081
Product Description
Mechanism of Action
R&D Progress
ALX-0081 + ALX-0681
Product Description
Mechanism of Action
R&D Progress
ALX-0141
Product Description
Mechanism of Action
R&D Progress
ALX-0171
Product Description
Mechanism of Action
R&D Progress
ALX-0681
Product Description
Mechanism of Action
R&D Progress
ALX-0761
Product Description
Mechanism of Action
R&D Progress
ATN-192
Product Description
Mechanism of Action
R&D Progress
Drug 1 For Inflammation And Immunology
Product Description
Mechanism of Action
R&D Progress
Drug 2 For Inflammation And Immunology
Product Description
Mechanism of Action
R&D Progress
Drug For Pulmonary Diseases
Product Description
Mechanism of Action
R&D Progress
ozoralizumab
Product Description
Mechanism of Action
R&D Progress
Ablynx NV - Pipeline Analysis
Ablynx NV - Pipeline Products by Therapeutic Class
Ablynx NV - Pipeline Products by Route of Administration
Ablynx NV - Pipeline Products By Mechanism of Action
Ablynx NV - Recent Pipeline Updates
Ablynx NV - Dormant Projects
Ablynx NV - Company Statement
Ablynx NV - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Ablynx NV, Recent Developments
Ablynx NV- Press Release
Jun 25, 2012: Ablynx Announces New Compelling Results On Ozoralizumab In Rheumatoid Arthritis
Dec 22, 2009: Ablynx Announces Phase Ib Study Results Of ALX-0081 For The Treatment Of Acute Coronary Syndrome
Dec 14, 2009: Ablynx Initiates Phase I Trial Study Of ALX-0141 For The Treatment Of Postmenopausal Women
Sep 01, 2009: Ablynx Initiates Phase II Clinical Trial For ALX-0081
Aug 18, 2009: Ablynx Announces Positive Phase I Results For Subcutaneous Administration Of Its Anti-Thrombotic Nanobody (ALX-0681)
Jun 29, 2009: Ablynx Announces A Novel Preclinical Development Candidate Targeting IL6R
Mar 30, 2009: Ablynx Reports Detailed Positive Phase IB Results For Its Anti-Thrombotic Nanobody ALX-0081
Financial Deals Landscape
Ablynx NV, Deals Summary
Ablynx NV, Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Ablynx Secures $51 Million In Series C Financing
Partnerships
Ablynx Enters Into Licensing Agreement With Boehringer Ingelheim

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=468502&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.